References
- World Health Organization. Global Status Report on Alcohol and Health 2018. Geneva: World Health Organization; 2018. https://apps.who.int/iris/bitstream/handle/10665/274603/9789241565639-eng.pdf.
- Sacks JJ, Gonzales KR, Bouchery EE, et al. 2010 national and state costs of excessive alcohol consumption. Am J Prev Med. 2015;49(5):73–79.
- Saitz R. Clinical practice. Unhealthy alcohol use. N Engl J Med. 2005;352(6):596–607.
- Stahre M, Roeber J, Kanny D, et al. Contribution of excessive alcohol consumption to deaths and years of potential life lost in the United States. Prev Chronic Dis. 2014;11:130293. https://doi.org/http://doi.org/10.5888/pcd11.130293
- Meadows SO, Engel CC, Collins RL, et al. 2015 Department of Defense Health Related Behaviors Survey (HRBS). RAND report 1695. 2018. https://www.rand.org/pubs/research_reports/RR1695.html.
- Bray RM, Pemberton MR, Hourani LL, et al. 2008 Department of Defense Survey of Health Related Behaviors among Active Duty Military Personnel. Research Triangle Park, NC: Research Triangle Institute; 2009.
- Bray RM, Pemberton MR, Lane ME, et al. Substance use and mental health trends among U.S. military active duty personnel: key findings from the 2008 DoD Health Behavior Survey. Mil Med. 2010;175(6):390–399.
- Bray RM, Hourani LL. Substance use trends among active duty military personnel: findings from the United States Department of Defense Health Related Behavior Surveys, 1980–2005. Addiction. 2007;102(7):1092–1101.
- United States Department of Health and Human, Assistant Secretary for Planning and Evaluation. Review of medication-assisted treatment guidelines and measures for opioid use and alcohol use. Washington, D.C. 2015. https://aspe.hhs.gov/report/review-medication-assisted-treatment-guidelines-and-measures-opioid-and-alcohol-use/e-summary-medication-assisted-treatment-quality-measures.
- Harwood HJ, Zhang Y, Dall TM, et al. Economic implications of reduced binge drinking among the Military Health System’s TRICARE prime plan beneficiaries. Mil Med. 2009;174(7):728–736.
- Armed Forces Health Surveillance Branch. Alcohol-related diagnoses, active component, U.S. Armed Forces, 2001–2010. MSMR. 2011;18(10):9–13.
- Benjamin KL, Bell NS, Hollander IE. A historical look at alcohol abuse trends in Army and civilian populations. Mil Med. 2007;172(9):950–955.
- Psychological Health Center of Excellence. Psychological Health by the Numbers: Mental Health Disorder Prevalence and Incidence among Active Duty Service Members, 2005–2017. Falls Church, VA: Defense Health Agency; 2019. https://www.pdhealth.mil/research-analytics/psychological-health-numbers/mental-health-disorder-prevalence.
- Institute of Medicine. Substance Use Disorders in the U.S. Armed Forces. Washington, DC: The National Academies Press. 2013.
- United States Department of Veterans Affairs & Department of Defense. VA/DoD clinical practice guideline for the management of substance use disorders (Version 3.0). Washington, D.C.: VA/DOD Evidence Based Practice Guideline Work Group; 2015. https://www.healthquality.va.gov/guidelines/mh/sud/.
- Substance Abuse and Mental Health Services Administration and National Institute on Alcohol Abuse and Alcoholism. Medication for the Treatment of Alcohol Use Disorder: A Brief Guide. HHS Publication No. (SMA) 15-4907. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015. https://store.samhsa.gov/product/Medication-for-the-Treatment-of-Alcohol-Use-Disorder-A-Brief-Guide/SMA15-4907.
- Botticelli MP. Memorandum to heads of executive departments and agencies: Changing federal terminology regarding substance use and substance use disorders. Executive Office of the President, Office of National Drug Control Policy; January 9, 2017. https://www.whitehouse.gov/sites/whitehouse.gov/files/images/Memo%20-%20Changing%20Federal%20Terminology%20Regrading%20Substance%20Use%20and%20Substance%20Use%20Disorders.pdf.
- Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311(18):1889–1900.
- Rösner S, Hackl-Herrwerth A, Leucht S, et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;(12):CD001867. Published 2010 Dec 8. https://doi.org/http://doi.org/10.1002/14651858.CD001867.pub2.
- Garbutt JC, Kranzler HR, O'Malley SS, Vivitrex Study Group, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. JAMA. 2005;293(13):1617–1625.
- Harris AHS, Bowe T, Del Re AC, et al. Extended release naltrexone for alcohol use disorders: Quasi-experimental effects on mortality and subsequent detoxification episodes. Alcohol Clin Exp Res. 2015;39(1):79–83.
- Abraham AJ. Improving medication use in addictions treatment. Vol. 3. In: Miller PM, ed. Comprehensive Addictive Behaviors and Disorders. New York: Elsevier; 2013: 675–685
- Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet. 2003;361(9370):1677–1685.
- Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14):1641–1651.
- Rieckmann T, Muench J, McBurnie MA, et al. Medication-assisted treatment for substance use disorders within a national community health center research network. Subst Abus. 2016;37(4):625–634.
- Knudsen HK, Roman PM. Service delivery and pharmacotherapy for alcohol use disorder in the era of health reform: data from a national sample of treatment organizations. Subst Abus. 2016;37(1):230–237.
- Knudsen HK, Roman PM. Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders. J Stud Alcohol Drugs. 2014;75(3):467–475.
- Knudsen HK, Abraham AJ, Roman PM. Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011;5(1):21–27.
- United States Department of Veterans Affairs & Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (Version 2.0). Washington, D.C.: VA/DOD Evidence Based Practice Guideline Work Group; 2009. https://www.healthquality.va.gov/guidelines/MH/sud/sud_full_601f.pdf.
- Del Re AC, Gordon AJ, Lembke A, et al. Prescription of topiramate to treat alcohol use disorders in the Veterans Health Administration. Addict Sci Clin Pract. 2013;8(1):12.
- Harris AH, Kivlahan DR, Bowe T, et al. Pharmacotherapy of alcohol use disorders in the Veterans Health Administration. Psychiatr Serv. 2010;61(4):392–398.
- Armed Forces Health Surveillance Branch. AFHSB surveillance case definitions: substance-related disorders. 2017. https://health.mil/Military-Health-Topics/Combat-Support/Armed-Forces-Health-Surveillance-Branch/Epidemiology-and-Analysis/Surveillance-Case-Definitions.
- Armed Forces Health Surveillance Branch. AFHSB surveillance case definitions: epilepsy. 2017. https://health.mil/Military-Health-Topics/Combat-Support/Armed-Forces-Health-Surveillance-Branch/Epidemiology-and-Analysis/Surveillance-Case-Definitions.
- Armed Forces Health Surveillance Branch. AFHSB surveillance case definitions: migraine headache. 2017. https://health.mil/Military-Health-Topics/Combat-Support/Armed-Forces-Health-Surveillance-Branch/Epidemiology-and-Analysis/Surveillance-Case-Definitions.
- Witkiewitz K, Roos CR, Mann K, et al. Advancing precision medicine for alcohol use disorder: replication and extension of reward drinking as a predictor of naltrexone response. Alcohol Clin Exp Res. 2019;43(11):2395–2405.
- Anton RF, Latham PK, Voronin KE, et al. Nicotine-use/smoking is associated with the efficacy of naltrexone in the treatment of alcohol dependence. Alcohol Clin Exp Res. 2018;42(4):751–760.
- Fucito LM, Park A, Gulliver SB, et al. Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence. Biol Psychiatry. 2012;72(10):832–838.
- Witkiewitz K, Votaw VR, Vowles KE, et al. Opioid misuse as a predictor of alcohol treatment outcomes in the COMBINE study: mediation by medication adherence. Alcohol Clin Exp Res. 2018;42(7):1249–1259.
- Kranzler HR. Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research. Alcohol. 2000;35(6):537–547.
- Abraham AJ, Roman PM. Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector. J Stud Alcohol Drugs. 2010;71(3):460–466.
- Adams RS, Dietrich EJ, Gray JC, et al. Post-deployment screening in the Military Health System: an opportunity to intervene for possible alcohol use disorder. Health Aff. 2019;38(8):1298–1306.
- Allen B, Nolan ML, Paone D. Underutilization of medications to treat opioid use disorder: what role does stigma play? Subst Abus. 2019;40(4):459–465.
- Robinson SM, Adinoff B. The mixed message behind “medication-assisted treatment” for substance use disorder. Am J Drug Alcohol Abuse. 2018;44(2):147–150.
- Guglielmo R, Martinotti G, Quatrale M, et al. Topiramate in alcohol use disorders: review and update. CNS Drugs. 2015;29(5):383–395.
- Aletraris L, Bond Edmond M, Roman PM. Adoption of injectable naltrexone in U.S. substance use disorder treatment programs. J Stud Alcohol Drugs. 2015;76(1):143–151.
- Harris AHS, Ellerbe L, Reeder RN, et al. Pharmacotherapy for alcohol dependence: Perceived treatment barriers and action strategies among Veterans Health Administration service providers. Psychol Serv. 2013;10(4):410–419.
- Harris AHS, Bowe T, Hagedorn H, et al. Multifaceted academic detailing program to increase pharmacotherapy for alcohol use disorder: interrupted time series evaluation of effectiveness. Addict Sci Clin Pract. 2016;11(1):15.
- Hourani L, Bender R, Weimer B, et al. Comparative analysis of mandated versus voluntary administrations of post-deployment health assessments among marines. Mil Med. 2012;177(6):643–648.
- Secretary of the Army. Army directive 2019–12 (policy for voluntary alcohol-related behavioral healthcare). 2019. https://armypubs.army.mil/epubs/DR_pubs/DR_a/pdf/web/ARN16186_AD2019-12_Web_Final.pdf.